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ABSTRACT 
Introduction and Objective: The costs of the insulin analogue (Insulin glargine) have been 
growing appreciably in the State of Minas Gerais in Brazil, averaging 291% per year in recent 
years. This growth has been driven by an increasing number of successful law suits and a 
536% price difference between insulin glargine and neutral protamine Hagedorn (NPH) 
insulin. One potential way to address this is to undertake a systematic review assessing the 
efficacy and safety of insulin glargine analogue compared with NPH insulin in patients with 
Type I diabetes. As a result, provide published data to support future recommended activities 
by the State of Minas Gerais. These could include maintaining it on the list of the Public 
Health System (SUS) provided there is a price reduction. Alternatively, provide potential 
arguments to defend against future law suits should the authorities decide to delist insulin 
glargine. 
Methods: A systematic review of published studies researching the effectiveness of insulin 
glargine in patients with Type 1 diabetes between January 1970 and July 2009 in Medline 
(PubMed), the Latin American and Caribbean Centre on Health Sciences Information, the 
Cochrane Controlled Trials Databases and the National Health Service (NHS) Centre for 
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Reviews and Dissemination. Inclusion criteria included insulin glargine on its¶ own or 
combined with other insulin formulations. Only randomised controlled clinical trials were 
included. Initially, the titles of all studies were assessed by two independent reviewers before 
being potentially discarded, with the quality of papers assessed using a modified Jadad scale. 
The outcome measures included blood levels of glycated haemoglobin, episodes of 
hypoglycaemia, adverse effects and the reduction of microvascular and macrovascular end-
organ complications of T1DM.  
Results: Out of 803 studies found in the selected databases, only eight trials met the inclusion 
criteria. Most of the studies were of poor methodological quality or had a high risk of bias 
with a mean score of 2.125 on the Jadad scale. No study could be classified as double-blind, 
and only one study documented the increased efficacy of insulin glargine in relation to both 
glycaemic control and hypoglycaemic episodes. Typically, there was no significant difference 
between insulin glargine and NPH insulins. 
Conclusions: This systematic review showed no therapeutic benefit of insulin 
glargine over other insulin formulations studied when analysing together glycaemic 
control and the frequency and severity of hypoglycaemia. We therefore recommend 
to the State Authority to delist insulin glargine or renegotiate a price reduction with 
the manufacturer. This systematic review provides support for this decision as well 
as documentation to combat potential law suits if there cannot be satisfactory 
discussions. 
 
Key points for decision makers 
 
x The costs of insulin glargine have been growing appreciably in the State of Minas Gerais 
in Brazil in recent years. This has been driven by an increasing number of successful law 
suits and substantial price differential between long-acting insulin analogues and other 
insulin formulations 
x A thorough systematic review would provide a rationale whether to maintain insulin 
glargine on the list of the Public Health System (SUS) or delist it. In addition, provide 
potential arguments to defend against future law suits if pertinent 
x The review showed no clinical benefit with insulin glargine over other insulin 
formulations, confirming the findings from other reviews 
x This provides a basis for the State Government to seek either to delist insulin glargine or 
negotiate a price reduction similar to other countries 
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INTRODUCTION 
There is increasing scrutiny on pharmaceutical expenditure among countries, driven by 
expenditure rising by more than 50% in real terms between 2000 and 2009 among OECD 
countries [1-6]. This has been driven by well known factors including ageing populations, 
rising patient expectations and the continued launch of new premium priced drugs. As a 
result, there will be continued growth in pharmaceutical expenditure unless there are further 
reforms to address this. Ongoing initiatives among countries to moderate growth rates in 
pharmaceutical expenditure include processes to robustly assess the value of new drugs 
against existing standards and link this to reimbursed prices, encourage the prescribing of low 
cost alternatives when care is not compromised, and disinvest in products that are seen to no 
longer provide value [1-4, 6, 7]. An example of the latter is Sweden, which re-assessed the 
value of nearly 2,000 pharmaceuticals across a number of disease areas. These included drugs 
to treat migraine, excessive stomach acid, respiratory diseases, hypertension, depression, and 
hyperlipidaemia [3, 5, 8-11]. Following the review of respiratory diseases, cough medicines 
were delisted as the reimbursement agency (TLV) believed it was unreasonable to reimburse 
these medicines with only limited efficacy and for short-term conditions with only relatively 
minor discomfort. Four asthma treatments were delisted from October 2007 including 
theophyllines for maintenance treatment as they were considered not cost-effective against 
newer treatments [3, 5]. Prescribing restrictions have also been introduced for some patented 
drugs in Sweden [8-11]. These included angiotensin receptor blockers versus generic 
angiotensin converting enzyme inhibitors (ACEIs), patented statins versus generic statins and 
duloxetine [8-11]. Duloxetine was restricted to patients suffering from depression or general 
anxiety disorders who had been prescribed at least two other antidepressants and not reached 
their treatment goals [9, 11]. The French reimbursement agency has also evaluated over 4000 
products. This is because products of no real therapeutic value cost the French health service 
RYHU¼PQ\HDUbefore the start of the review [6]. The first wave of the reviews resulted in 
72 products being removed from the reimbursement list. 282 products were removed in 2006, 
with more products delisted in recent years [6]. 
Recent reforms in Germany resulted in the delisting of atorvastatin from the reimbursement 
list as there was no outcome data showing superiority over generic simvastatin but a 
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considerably higher price [l2]. IQWIG also recommended the delisting of long-acting insulin 
analogues as there was no outcome data demonstrating superiority over neutral protamine 
Hagedorn (NPH) insulins to justify appreciably higher prices in both Type I and II diabetes 
[13-16]. This led to price reductions of long-acting insulins soon after the initial activities to 
help maintain reimbursement for these drugs, which have persisted [17]. The findings are 
similar to those from the Cochrane Review of long-acting insulins, which also found long-
acting insulins only have a minor clinical benefit, if at all, versus NPH insulins in patients 
with Type I or II diabetes [18, 19]. NICE in the UK in 2002 recommended NPH insulins as 
first line treatment in patients with Type II diabetes, with long-acting insulins only 
recommended in specific circumstances, with glargine a potential option for patients with 
Type I diabetes (14, 20). The specific circumstances were (20): 
x Those who require assistance from a carer or healthcare professional to administer their 
insulin injections. 
x Those whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemic 
episodes. 
x Those who would otherwise need twice-daily basal insulin injections in combination with 
oral antidiabetic drugs. 
Similarly, the Pharmaceutical Management Agency (PHARMAC) in New Zealand only 
approved long acting insulins for reimbursement as second line therapy [21]. This includes 
patients who are allergic to conventional insulins or have failed to control their diabetes with 
conventional insulins [21]. In Canada, the Canadian Agency for Drugs and Technologies in 
Health similarly only recommended long acting insulins in patients experiencing significant 
hypoglycaemia with human insulins [14]. This is perhaps not surprising with a number of 
published studies showing at best only modest health gain with the long-acting insulins [14, 
19, 22, 23]. 
The State of Minas Gerais in Brazil has also introduced a number of measures to enhance the 
quality and efficiency of future prescribing. This includes the instigation of the Commission 
of Pharmaceuticals and Therapeutics (Comissão de Farmácia e Terapêutica ± CFT) [24]. The 
Commission has a mandate to recommend the inclusion and exclusion of drugs funded by the 
State and distributed by the state branch of the public healthcare system (Sistema Único de 
Saúde - SUS/MG) [24]. The reviews are based on available scientific evidence of relative 
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efficacy, safety and cost-effectiveness versus current standards [24], mirroring activities in a 
number of European countries [3, 4, 6, 14, 25-27]. Consequently, providing a scientific basis 
for potential future activities and deliberations by the State authorities. This is because in 
Brazil the government subsidises the list of medicines to be provided to the population. When 
doctors do not prescribe certain drugs as they are not included in the standard list of publically 
available drugs, some patients subsequently sue the state to try and obtain them. This is 
because under Brazilian law, there is a constitutional principle of universality and 
comprehensiveness [28]. However, this system can be abused as illustrated by 2,412 lawsuits 
between October 1999 and 2009 [28], particular via the private sector. As a result, helping to 
serve the interest of pharmaceutical companies rather than health authorities with their fixed 
budgets [28]. The belief is that thorough systematic reviews will provide robust arguments to 
successfully combat future lawsuits. 
Insulin analogues were originally developed to improve the safety, efficacy and comfort of 
treating patients with diabetes mellitus. Such drugs have a chemical structure analogous to 
that of insulin and are classified as long-acting (glargine and detemir) or fast-acting (lysine-
proline (lispro), glulisine and aspart). 
Insulin glargine was the first insulin analogue developed. Its use in humans was approved by 
the European Medicines Agency in 2000, and it was introduced into clinical practice in the 
early years of the last decade. In Brazil, this drug was registered by the National Health 
Surveillance Agency (Agência Nacional de Vigilância Sanitária - ANVISA) in 2003, when it 
also began to be marketed. The drug was marketed as an improved reduction of 
hypoglycaemic episodes and increased comfort for patients despite limited confirmatory 
evidence [29], leading to a rapid uptake. 
Initially, insulin glargine was not included in the medicines list of the State of Minas Gerais. 
However, an increasing number of lawsuits compelled the State government to include insulin 
glargine in 2005 in the State of Minas Gerais¶ List of Medicines for patients with type 1 
diabetes. This though did not stop the lawsuits for patients outside the current protocol, e.g. 
patients with type 2 diabetes, in view of the price differential between NPH insulins and 
glargine insulins. 
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Between 2005 and 2006, insulin glargine was responsible for the third highest number of 
lawsuits filed against the State Health Secretary (Secretaria de Estado de Saúde - SES/MG) 
[30]. Overall, the number of administrative requests has grown since insulin glargine was 
included in the State List of Medicines, corresponding to 2,632* people. At the same time, the 
expenses of Minas Gerais State Treasury with insulin glargine grew an average of 291% per 
year, reaching almost US$ 6 million in 2011** (Figure 1). In Brazil, the cost of treating with 
insulin glargine is 536% that of treatment with NPH insulin [31]. 
Figure 1 Expenditure on insulin glargine by Minas Gerais State, Brazil (2007-2011) in US$ 
 
  
NB. There is no adjustment for inflation 
In addition in 2009, CFT/SUS/MG was informed of the results of studies indicating a higher 
risk of malignancy in diabetic patients treated with insulin analogues [32, 33]. This, together 
with the concerns with the value of insulin glargine versus NPH insulins, motivated SES/MG 
to request to the Collaborating Centre for Phamacoeconomic and Epidemiologic Studies of 
the Federal University of Minas Gerais, a partner of SES/MG in technical-scientific studies, to 
perform a systematic review assessing the efficacy and safety of the insulin analogue glargine 
in patients with type 1 diabetes (T1DM). 
Consequently the objective of this study is to assess the efficacy and safety of insulin glargine 
compared with NPH insulin in patients with Type I diabetes based on a full systematic review 
of currently available evidence. This builds on previous reviews [16,18,20,22,23,34]. 
Subsequently, use the findings to evaluate whether to maintain insulin glargine on the list of 
                                                 
*Data from the Integrated System of Pharmaceutical Assistance Management of the State Health Secretary 
(SES/MG) in December 2011. 
**Data from the Direction of High-Cost Medicines (SES/MG) in February 2012. USD 1 = BRL 1,72  
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the Public Health System (SUS) in the Minas Gerais State in Brazil. Alternatively, provide 
published data to support future recommended activities by the State of Minas Gerais. This 
could include suggesting that the State subsequently negotiates price reductions with the 
manufacturer. In addition, provide potential arguments to defend against future law suits 
when these occur in the absence of successful negotiations. 
METHODS 
A systematic review was performed using the software Reference Manager to identify 
potentially relevant studies published between January 1970 and July 2009 in Medline 
(PubMed), the Latin American and Caribbean Centre on Health Sciences Information 
(Literatura Latino-Americana e do Caribe em Ciências da Saúde - LILACS), the Cochrane 
Controlled Trials Databases and the National Health Service (NHS) Centre for Reviews and 
Dissemination. The studies selected dealt with the efficacy/effectiveness of insulin glargine in 
the treatment of patients with T1DM and included a survival analysis, the definition of a 
response and adverse effects. 
The following keywords in Portuguese, English and Spanish were used in the search: type 1 
diabetes mellitus, glargine insulin, NPH insulin, regular insulin, animal NPH insulin, 
recombinant NPH insulin, animal regular insulin, recombinant regular insulin, humans, 
efficacy, effectiveness and cost-effectiveness. 
An illustration of the search strategy for Pub Med is included in the Appendix (Appendix 1). 
The following analysis criteria were established regarding the inclusion of studies in the 
review:  
1. Intervention: monotherapy with insulin glargine or combined regimens with other 
insulin formulations 
2.  Type of study: randomised controlled clinical trials including comparisons between 
drugs used in the treatment of patients with T1DM, other insulins or best supportive 
care (systematic reviews of clinical trials identified during the search were also used in 
the comparison and discussion of results). 
The exclusion criteria included the following:  
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x studies published in languages other than English, Portuguese and Spanish; 
x studies not performed in humans 
x those unrelated to T1DM  
x studies lacking at least one of the outcome measures of efficacy and/or safety. 
Initially, to verify whether they complied with the inclusion criteria, the titles of all the studies 
located were assessed. Next, two independent reviewers (AS and RN) also assessed the 
abstracts. A third reviewer (LD) subsequently analysed studies where there was no inter-
reviewer agreement regarding potential inclusion. 
The outcome measures considered included the following: blood levels of glycated 
haemoglobin, episodes of hypoglycaemia, adverse effects and the reduction of microvascular 
and macrovascular end-organ complications of T1DM.  
A modified Jadad scale was used to assess the methodological quality of the randomised 
controlled clinical trials [35]. The assessment of the quality of the studies was also performed 
by two independent reviewers (AS and RN), with input from a third reviewer (LD) in cases of 
disagreement between the two reviewers. 
The study was approved by the Research Ethics Committee of the Federal University of 
Minas Gerais (Ruling nº ETIC 0588.0.203.000-09).  
RESULTS 
Search Strategy 
The initial search strategy identified 803 titles and abstracts (Figure 2). Of these 803 studies, 
666 were excluded based on their titles. These included nine studies that had not been 
performed in humans, 108 were not related to T1DM, 546 did not describe comparative 
results of the effectiveness of the investigated drugs and three did not report on at least one of 
the considered outcome measures of efficacy/effectiveness (blood level of glycated 
haemoglobin, measurements of glycaemia, episodes of hypoglycaemia, reduction of 
microvascular and macrovascular events, adverse effects, survival analysis). The abstracts of 
the remaining 137 studies were subsequently analysed. Of these, six, four, 64 and five (for a 
total of 79), respectively, were excluded for the same reasons mentioned above (Figure 2). 
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Studies initially identified in 
the search: 803 
Included titles: 137 
Excluded titles: 666 
 
Reasons 
 
Not performed in humans: 9 
 
Not related to T1DM: 108 
 
Not presenting comparative 
results regarding the 
effectiveness of the drugs 
studied: 546 
 
Not presenting at least one of the 
outcome measures of 
efficacy and/or 
safety consideration: 3 
 
 
Final list of Clinical trials: 8 
Excluded abstracts: 79 
 
Reasons 
 
Not performed in humans: 6 
 
Not related to T1DM: 4 
 
Not presenting comparative 
results regarding the 
effectiveness of the drugs 
studied: 64 
 
Not presenting at least one of 
the outcome measures of 
efficacy and/or 
safety consideration: 5 
Figure 2 - Schematic presentation of the articles included and excluded in the systematic        
review 
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A total of 58 studies remained for complete review. 50 of which were classified as studies on 
effectiveness based on observational data; consequently, these were excluded under our 
inclusion criteria. As a result, only eight papers using formal clinical trials were selected for 
analysis. One of these could not be retrieved; consequently was excluded. However, one 
additional study was subsequently found and selected following a manual search, making a 
total of eight studies for the systematic review (Table 1). 
The eight clinical trials scored an average of 2.125 points on the methodological assessment 
scale. According to Table 1, no study had score of 5 or 6, which represents high quality/low 
risk of bias. Three studies had scores of 3 or 4, which indicate appropriate quality/moderate 
risk of bias and five studies had a score of 0 to 2, denoting poor quality/high risk of bias. 
According to the Jadad criteria, the main limitations identified were: data collectors or 
evaluators were not blinded (eight studies); inappropriate randomisation method (five 
studies); lack of intention-to-treat (ITT) analysis (three studies with a further one where a full 
ITT analysis was not performed) and failure to describe the excluded participants or dropouts 
(one study) (Table 1).  
 Table 1 Clinical trial classification based on the modified Jadad scale 
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Rosenstock et al., 2000 [37] 1 0 -1 0 0 1 1 2 
Raskin et al., 2000 [40] 1 1 0 0 0 1 1 4 
Pieber et al., 2000 [38] 1 0 -1 0 0 0 0 0 
Schober et al., 2002 [42] 1 0 -1 0 0 1 0* 1 
Doyle et al., 2004 [39] 1 1 0 0 0 1 1 4 
Chatterjee et al., 2007 [41] 1 1 0 0 0 1 0 3 
Chase et al., 2008 [43] 1 0 -1 0 0 1 1 2 
White et al., 2009 [36] 1 0 -1 0 0 1 0 1 
*A full ITT analysis ZDVQRWSHUIRUPHGKHQFHWKHGRZQJUDGHIURPµ¶WRµ¶ 
All of the eight clinical trial studies were open-label and investigated the use of the insulin 
glargine administered once per day. The lack of blinding was justified by the authors by the 
different physical appearances of different insulin formulations. In the study by White et al 
(2009) [36], the assessment of the results was blinded, and in the studies by Rosenstock et al. 
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(2000) [37] and Pieber et al. (2000) [38], which compared two different concentrations of 
insulin glargine to another insulin formulation, the comparison between the different 
concentrations of insulin glargine was blinded. All of the studies were described as 
randomised; three among them, namely, Doyle et al. (2004) [39], Raskin et al. (2000) [40] 
and Chatterjee et al. (2007) [41], mentioned the method used for randomisation. An ITT 
analysis was described in five studies; however, in one of them, Schober et al. (2002) [42], the 
analysis was not performed on the full ITT population and thus was rated as inappropriate. As 
a result, this study was downgraded on its modified Jadad score (Table 1). 
Characteristics of the eight clinical trials 
Seven studies compared the efficacy of insulin glargine to NPH insulin, and the study by 
Doyle et al. (2004) compared the efficacy of insulin glargine to the continuous subcutaneous 
insulin infusion (CSII) of the analogue aspart [39]. None of the selected clinical trials 
compared the two long action analogues available, namely, insulin glargine and detemir. The 
median number of participants included was 168 (range 32-619), and the duration of follow-
up varied between one month (Rosenstock et al., 2000 and Pieber et al., 2000) [37, 38] and 
two years (Chatterjee et al., 2007) [41] with a median of four months (Table 2). 
With respect to the loss of participants during the study, Pieber et al. (2000) did not mention 
how many patients completed the study [38]. In the study by White et al. (2009), 23.4% of 
participants were lost [36], and in the remainder of studies, the loss was less than 12% (Table 
2). 
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Rosenstock et al 
(2000)  
United States of 
America [37] 
18-70  Insulin glargine30 40 
Insulin glargine80 42 
NPH Insulin 41 
Total 123 (48%) 
white 93,8% Insulin Glargine + 
regular 
Insulin NPH + 
regular  
 
To assess two formulations of 
insulin glargine in safety and 
efficacy in treating patients 
with T1DM. 
257 1 256 (99,6) Sanofi-
aventis 
2 
Raskin et al (2000) 
Canada [40] 
18-80  306 (49,4%) white 600 
black 16 
hispanic 9 
others 3 
Insulin Glargine + 
lispro 
NPH Insulin + 
lispro  
 
To assess insulin glargine 
efficacy and safety as a basal 
component in T1DM. 
 
619 4 588 (94,9) Sanofi-
aventis 
4 
Pieber et al7 (2000) 
France [38] 
18-70 130 (39%) - HOE 901 + regular 
NPH + regular 
To compare the efficacy of 
HOE 901 with NPH in T1DM. 
 
333 1 - Sanofi-
aventis 
0 
Schober et al 
(2002) 
Austria [42] 
5-16 Insulin glargine 77 
(44,3%) 
NPH Insulin 91 
(52%) 
total 168 (48,1%) 
- Insulin glargine + 
regular 
NPH Insulin + 
regular 
To compare efficacy and safety 
of insulin glargine with NPH 
T1DM children and adolescent. 
361 6 349 (96,7) Sanofi-
aventis 
1 
Doyle et al (2004) 
United States of 
America [39] 
8-21  18 (56,2%) white 24 
hispanic 5  
black 3 
Insulin Glargine 
+aspart 
aspart 
To compare the efficacy of 
CSII to MDI with insulin 
glargine in lowering HbA1c 
levels in children and 
adolescents with type 1 
diabetes. 
32 4 31 (96,8) Sanofi-
aventis 
Novo 
Nordisk 
4 
Chatterjee et al 
(2007) 
England [41] 
18-75 27 (45%) european 58 
south asian 2 
Insulin glargine + 
aspart 
NPH + aspart 
To compare the efficacy of 
insulin glargine and aspart with 
NPH insulin and aspart in a 
basal bolus regimen in type 1 
diabetes. 
60 2
4 
53 (88,3) Sanofi-
aventis 
Novo 
Nordisk 
3 
 
 
74 
 
Table 2 Characteristics of the selected clinical trials 
T
ri
a
l 
A
g
e 
g
ro
u
p
 
S
ex
 (
fe
m
a
le
) 
 
(n
, 
%
) 
E
th
n
ic
 g
ro
u
p
  
(n
, 
%
) 
In
te
rv
e
n
ti
o
n
 
T
ri
a
l 
a
im
 
P
a
r
ti
ci
p
a
n
ts
 (
n
) 
F
o
ll
o
w
-u
p
 p
er
io
d
 
 (
m
o
n
th
s)
  
P
a
r
ti
ci
p
a
n
ts
 
in
n
cl
u
id
ed
 t
r
ia
l 
 
n
 (
 %
) 
S
p
o
n
so
r 
J
a
d
a
d
 s
co
r
e 
Chase et al (2008) 
United States of 
America [43] 
9-17 Insulin glargine 45 
(53,6%) 
NPH/lente 44 
(52,4%) 
Total 52,9% 
white  
insulin glargine 71 
(84,5%) 
NPH/lente 68 (81%) 
black 
insulin glargine 0 
(0%) 
NPH/lente 7 (8,3%) 
asian 
insulin glargine 2 
(2,4%) 
NPH/lente 2 (2,4%)  
hispanic 
insulin glargine 7 
(8,3%) 
NPH/lente 4 (4,8%) 
multiracial 
insulin glargine 2 
(2,4%) 
NPH/lente 1 (1,2%) 
other 
insulin glargine 2 
(2,4%) 
NPH/lente 2 (2,4%) 
Insulin glargine + 
lispro 
NPH/lente + lispro 
To compare efficacy and safety of 
insulin glargine with NPH T1DM 
children and adolescent. 
 
175 6 157 (89,7) Sanofi-
aventis 
2 
White et al (2009) 
United States of 
America [36] 
9-17 42 (46,6%) white 81  
asian 2 
hispanic 5 
multiethnic 1 
other 1 
Insulin glargine 
+lispro 
NPH/lente + lispro   
To compare efficacy and safety of 
insulin glargine with NPH/lente 
T1DM children and adolescent 
used as a basal component of a 
regime of multiple daily 
injections. 
90 6 69 (76,6) Sanofi-
aventis 
 
1 
T1DM: Type 1 diabetes mellitus; NPH: Neutral Protamine Hagedorn; HbA1c: Glycated hemoglobin; CSII: Continuous Subcutaneous Insulin Infusion; MDI: Multiple Daily 
Injection 
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Characteristics of participants and interventions in the eight clinical trials  
The minimum age of included participants was five years, and the maximum age was 80 
years. Of the 1,591 investigated participants, 56.76% were female, and 43.24% were male. 
Pieber et al. (2000) [38] and Schober et al. (2002) [42] did not distinguish between different 
ethnic groups; in the remainder of studies, most participants were Caucasian (Table 2).  
The selected studies compared insulin glargine prescribed once per day, NPH insulin 
administered once or twice daily as a basal treatment and the ultrafast-acting analogues lispro 
and aspart given in multiple injections or subcutaneous infusion as prandial components. 
Pieber et al. (2000) [38] and Schober et al. (2002) [42] used human regular insulin as a 
prandial component (Table 2). 
The following reasons were given for censoring in the studies: lost to follow-up, 
hypoglycaemia, adverse reaction to aspart, dehydration, pancreatic cancer (unrelated to 
treatment), lack of a baseline assessment of glycated haemoglobin A1c (HbA1c), adverse 
events, problems related to the monitoring mechanisms, automatic glycaemia (continuous 
glucose monitoring system, CGMS) and withdrawal of consent. 
Associated comorbidities were investigated but were not discussed in the selected studies. 
Outcome measures 
The efficacy of analogous glargine was assessed in all of the eight clinical studies (Table 3). 
White et al. (2009) did not find any statistically significant difference between insulin glargine 
and NPH insulin in terms of glycaemia measured by means of continuous automatic 
monitoring [36]. Fasting glycaemia was significantly improved with insulin glargine in 
Rosenstock et al. (2000): 81 mmol/L with insulin glargine (30ȝg/ml zinc), 86 mmol/L with 
insulin glargine (80ȝg/ml zinc) and 87 mmol/L with NPH (p<0.001) [37]; and in Schober et 
al. (2002): a 1.29 mmol/L reduction in the insulin glargine group versus 0.68 in the NPH 
group (p=0.02) [42]. Raskin et al. (2000) also documented the advantages of using insulin 
glargine over NPH in terms of the plasma and blood levels of fasting glucose, as assessed at 
baseline, at the time of any outcomes and every week [40]. However, the frequency of 
nocturnal hypoglycaemia was lower in users of NPH insulin than with glargine (p=0.06). 
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Table 3 Advantages in the reduction of Glycosylated Haemoglobin (HbA1c) and 
episodes of hypoglycaemia 
 
Estudo 
Statistically significant 
advantage in the reduction of 
episodes of hypoglycaemia 
Statistically significant 
advantage in the reduction of  
HbA1c  
 
Rosenstock et al., 2000 [37] NPH * 
Raskin et al., 2000 [40] NS NS 
Pieber et al., 2000 [38] Insulin glargine Insulin glargine 
Schober et al., 2002 [42] ** NS 
Doyle et al., 2004 [39] ** Aspart (continuous infusion) 
Chatterjee et al., 2007 [41] NS Insulin glargine 
Chase et al., 2008 [43] Insulin glargine NS 
White et al., 2009 [36] NS NS 
* Not assessed in the study; ** No p value documented; NS: No statistically significant NB. 
White et al did find a statistically significant advantage for insulin glargine for glucose levels but 
this did not translate into a statistically significant reduction in hypoglycaemia 
 
Pieber et al. (2000) found a significant difference (p=0.030) in the overall comparison of 
HbA1c values in the patients using insulin glargine (30ȝg/ml zinc and 80ȝg/ml zinc), with 
7.71% and 7.77%, respectively, compared to 7.88% with NPH [38]. Chatterjee et al (2007) 
documented a HbA1c outcome value of 8.07% in users of insulin glargine and 8.26% in users 
of NPH (p=0.04) [41]. With regard to the fasting plasma glucose level, the average values 
were 8.42 mmol/L in insulin glargine users and 11.42 mmol/L in NPH insulin users (p=0.01).  
Only one 16-week study (Doyle et al., 2004) directly compared insulin glargine and aspart 
[39]. The average HbA1c levels were 8.2 ± 1.1% in the glargine group and 8.1 ± 1.2% in the 
aspart CSII group (p<0.05). The number of patients who attained Hb$FOHYHOVLQthe 16 
weeks were two (12.5%) and eight (50%) (p<0.05), respectively. 
The literature mentions a reduction in the episodes of hypoglycaemia as a possible advantage 
of insulin glargine. When White et al. (2009) analysed this, they found a significant 
difference in the adjusted average glucose levels in the insulin glargine group at <50 mg/dL 
(<2.78 mmol/L; p=0.0198) and <40 mg/dL (<2.22 mmol/L; p=0.0130) compared to the 
NPH/slow-acting insulin group (p=0.0298) [36]. However this did not translate into a 
statistically significant reduction in the incidence of hypoglycaemia. Pieber et al  (2000) 
though showed insulin glargine significantly reduced the incidence of hypoglycaemia when 
compared to NPH insulin [38]. Chase et al also proved the superiority of insulin glargine 
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when they assessed the incidence of hypoglycaemia between 50 mg/dL and 70 mg/dL [43]. 
However, Rosenstock et al. (2000) observed a significant difference favouring NPH insulin 
despite insulin glargine improving fasting glycaemia [37]. All the patients in the HOE 901 
glargine (80ȝg/ml zinc) group, 97.5% of patients in the HOE 901 (30ȝg/ml zinc) group and 
93.2% of those in the NPH group experienced at least one episode of hypoglycaemia 
(p=0.030). The remainder of studies did not report any statistically significant results.  
In the study by Doyle et al. (2004) [39], four patients in the glargine group experienced one 
episode of severe hypoglycaemia, and one patient in the continuous subcutaneous aspart 
infusion group developed nocturnal hypoglycaemia. However, these findings were not 
statistically significant.  
 
In the study by White et al. (2009), 17.6% of patients using insulin glargine and 8.9% of those 
using NPH/slow-acting insulin required treatment for severe adverse events [36]. In this same 
study, the average time to hypoglycaemia in week 24 was statistically shorter in the insulin 
glargine group. In the study by Chase et al. (2008), 15 (17.6%) patients using insulin glargine 
and 8 (8.9%) patients in the NPH/slow-acting insulin group reported adverse reactions; 
however, this difference did not reach statistical significance [43]. In terms of the incidence of 
severe adverse events, the frequency was higher in the insulin glargine group (p<0.05) in this 
study. 
Injection site reactions were described by four studies. Rosenstock et al. (2000) [37] and 
Pieber et al. (2000) [38] did not specify which group. In Raskin et al [40], pain was more 
common with insulin glargine (6.1%) than NPH insulin (0.35); however, haemorrhage was 
more common with NPH insulin at 4.2% vs. 3.2% with insulin glargine. In Schober et al. 
(2002) [42], injections site reactions occurred in 9.2% of patients on insulin glargine and 8.6% 
of patients with NPH insulin. Ketoacidosis occurred in one patient using insulin glargine in 
the study by Doyle et al. (2004) [39], as well as in one patient in the insulin glargine group 
(0.6%) and four patients (2.9%) in the NPH insulin group in the study by Schober et al. 
(2002) [42]. 
The body mass index (BMI) at baseline of the participants of all investigated studies varied 
between 18.8 and 25.7 and did not exhibit any significant alteration in the studies that 
assessed this variable during follow-up, namely, Chase et al. (2008) [43], Doyle et al. (2004) 
[39] and Chatterjee et al. (2007) [41]. 
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The following diabetes complications were investigated but were not addressed by any of the 
analysed studies: neuropathy, nephropathy, retinopathy, heart disease, effect on the brain 
vessels, neoplasias and hospitalisations. Consequently, no comment could be made in our 
systematic review. 
DISCUSSION 
This systematic review analysed the glycaemic control, as well as the frequency and severity 
of episodes of hypoglycaemia, that were associated with the treatment of patients with Type 1 
diabetes (T1DM) with either insulin glargine or NPH insulins. Although the analysis of 
isolated results indicated clinical benefits from insulin glargine in patients with T1DM in 
terms of a reduction of fasting glycaemia, insulin glargine did not show any advantages when 
this parameter was analysed together with a reduction of the frequency of episodes of 
hypoglycaemia with the control of glycaemia assessed by means of glycated haemoglobin 
apart from one study (Table 3). These results are consistent with the findings from the 
systematic review performed by the Institute of Quality and Efficiency in Health Care 
(IQWIG) in Germany [13, 16, 19], the review by the Cochrane collaboration as well as other 
recent reviews [14, 18-21]. These various reviews have resulted in a number of health 
authorities across continents either delisting long-acting insulins or relegating them to second 
line use [13-16, 19-21, 44, 45]. For instance in Scotland, the authorities recommend that 
insulin JODUJLQH VKRXOGRQO\EHXVHG LQSDWLHQWVZLWK7\SH ,GLDEHWHVZKRDUH µDW ULVNRIRU
experiencing unacceptable frequency and/ or severity of nocturnal hypoglycaemia on 
attempting to achieve better hypoglycaemic control during treatment with established insulins 
[44]. Demand side measures routinely used in Scotland to enhance adherence to this guidance 
include academic detailing, monitoring of physician prescribing and financial incentives [1, 2, 
46]. 
In the studies by Pieber et al. (2000) [38] and Chatterjee et al. (2007) [41], insulin glargine 
significantly reduced glycated haemoglobin levels compared to NPH insulin. However, due to the 
number of episodes of nocturnal hypoglycaemia, only the first study demonstrated an advantage in 
the use of insulin glargine (Table 3).  
Frequent episodes of nocturnal hypoglycaemia are also mentioned as an argument to justify 
the preferential use of analogues compared to other insulin formulations. However, among the 
studies that analysed this variable, only three reported statistically significant results (Table 
3). Raskin et al. (2000) obtained results favourable to NPH (p=0.06) but this was not 
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statistically significant [40]. Pieber et al. (2000) obtained results favourable to glargine and 
Chase et al (2008) proved the superiority of insulin glargine when they assessed the incidence 
of hypoglycaemia between 50 mg/dL and 70 mg/dL [38,43]. 
Doyle et al. (2004) reported improved results using continuous aspart infusion compared to 
glargine in the reduction of HbA1c on the 16th week of treatment [39]. However, this study 
only included 32 patients (Table 2).  
Singh et al. (2009) performed a meta-analysis which focused on the efficacy and safety of 
insulin analogues in the treatment of patients with type 1, 2 and gestational diabetes [22]. 
These researchers concluded that the fast- and slow-acting analogues exhibited little 
additional benefit over conventional insulin formulations in terms of the control of glycaemia 
or the reduction of episodes of hypoglycaemia. These authors further observed that higher 
quality studies with longer durations of follow-up are needed to establish whether the insulin 
analogues are able to reduce the risk of chronic complications of diabetes mellitus. Based on 
this study, the World Health Organisation requested an updated review to be assessed at the 
18th Expert Committee on the Selection and Use of Essential Medicines. This review 
concluded that the differences between long-acting insulin analogues and human insulin 
formulations are notably small. There was no clear clinical advantage from the use of long-
acting insulin analogues compared to human insulin, and the advantages found were 
inconsistent in terms of their statistical and clinical significance. In addition, the long-acting 
insulin analogues did not prove to be consistently cost-effective, and there is uncertainty as to 
their association with an increased risk for cancer. This review further emphasised the high 
risk of bias of the studies assessing long-acting insulin analogues, due to their low quality and 
the fact that many of the researchers in the studies had links to the pharmaceutical industry 
(2011) [47]. Consequently, endorsing the findings in our systematic review. 
Several other meta-analyses have reached similar conclusions [18-20,23].  This supports the 
recent recommendation by the Brazilian Network for Health Technology Assessment stating 
that resources ought to be employed in programmes seeking to maximise the treatments 
available in the public healthcare network, as the current evidence does not support the 
superiority of long-acting insulin analogues [31]. 
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A further issue concerning patients on insulin therapy is weight gain, which is a frequent 
finding in these cases. The present review was not able to reach any robust conclusions 
concerning the alterations of the BMI based on the selected studies.  
Several studies discussed the mitogenic potential of insulin analogues. Glargine exhibits a 
6.5-fold greater affinity for the insulin-like growth factor (IGF-1) receptor compared to 
human insulin and an eight-fold greater potential to stimulate the synthesis of DNA by human 
osteosarcoma cells [48]. Hemkens et al. (2009) found a higher incidence of cancer than 
expected in patients using glargine compared to human insulin [32]. A study performed in 
Sweden in 2009 found a greater incidence of breast cancer in women using insulin glargine in 
monotherapy compared to other insulin formulations, although the conclusion was not 
definitive [33]. Conversely, the study by Currie et al. (2009) did not find any association 
between the use of insulin analogues and an increased risk of cancer compared to human 
insulin [49]. Smith et al. (2009) observed that although the evidence is insufficient for 
conclusions, this possibility must be subjected to surveillance, and more prospective studies in 
this area are needed  [50].  
A further preoccupation derived from the increased affinity for the IGF-1 receptor is the 
possibility of a faster evolution of retinopathy, perhaps up to threefold higher in patients using 
insulin glargine compared to those taking human insulin. Nevertheless, an analysis requested 
by the Food and Drug Administration (FDA) dispelled this concern, as reported by Smith et 
al. (2009) [50].  
Despite the concern with the chronic complications of diabetes and the mitogenic effects 
attributed to insulin analogues, none of the analysed studies investigated their influence on 
such conditions. The systematic review performed by Plank et al. (2005) observed that other 
possible long-term undesirable effects have also not yet been studied [34]. We acknowledge 
that we have not fully discussed the safety of long-acting insulins. However, the study length 
of the clinical trials did not allow us to fully review these. Consequently, we are unable to 
comment further on the long term safety of insulin glargine 
Given the increased use of insulin analogues in young females with T1DM, the safety profile 
of such drugs in pregnancy has paramount importance. However, none of the analysed studies 
included insulin-dependent pregnant women. 
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Despite the findings from the various reviews and health authority deliberations [14,16,18-
20,23,44,45,47], there is growing use of long-acting insulins across countries and in this State 
[14,20,45,51]. This is despite the appreciably increased costs of insulin glargine versus NPH 
insulins. Potential reasons for the continued growth in their sales include marketing activities 
by pharmaceutical companies targeting healthcare providers; attractive devices for the 
administration of long-acting insulin analogues that facilitate application and entice patients; 
removal of less expensive insulin formulations from the market; and reduced weight gain 
[29].  Cohen and Carter (2010) in their review discussed the relationship between the 
increased use of long-acting insulins and the lack of evidence of increased effectiveness and 
improved safety of insulin glargine and NPH insulins [29]. 
From a methodological perspective, the assessed studies scored low, primarily between 0 and 
2, which denotes poor methodological quality/high risk of bias. All studies were open-label, 
which are admittedly more prone to methodological bias.  
Such methodological difficulties were justified by the authors, as the macroscopic physical 
differences among insulin formulations make blinding impossible with regard to both 
experimental subjects and investigators. However, blinding is recommended, at least when 
assessing the results or in the titration of doses, which has been rarely mentioned as having 
been performed in actual practice, as the method used for randomisation was not described. 
In addition, Gill et al (2010) observed that the cost-benefit ratio of insulin glargine does not 
support its use, particularly in low income countries, although it might be indicated in specific 
conditions when there are sufficient resources [51].  
Although studies reporting economic assessments were not the subject of this present 
systematic review, given the higher monthly cost and the lack of clear therapeutic advantages 
of insulin glargine compared to NPH insulin, the cost-effectiveness ratio seems to favour the 
use of the latter. For this reason, the manufacturer of insulin glargine should present the 
Unified Health System (SUS) managers with reasons justifying the higher cost of this drug, 
including any new evidence as well as more accurate assessments of its cost-effectiveness and 
impact on quality-adjusted life years (QALY) vs. NPH insulins. Otherwise, seek a price 
reduction to address concerns with the value of insulin glargine versus NPH insulins. This is 
because a recent UK study estimated potential savings of up to GB£625million over the 
decade with greater use of NPH insulins versus long-acting insulins [14]. The savings would 
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have been higher with a greater differential between the cost of the various insulins, e.g. 
insulin glargine in the UK is less than double the cost of NPH insulin [14], appreciably lower 
than the 536% differential seen in the State of Minas Gerais. If price reductions are not 
achieved, the authorities in the State of Minas Gerais should seek to delist insulin glargine 
from the state list of medicines. Both activities are in line with the activities already 
undertaken by the authorities in Germany. The alternative is to restrict the funding and use of 
long-acting insulins to second line, which is similar to the current situation in the UK [14, 20, 
44]. However, this requires robust systems of physician monitoring and incentives to make 
sure the objectives of such initiatives are met; otherwise there will be disappointment [1, 2, 
52-54]. Consequently, we believe the authorities should in the first instance seek price 
reductions from the manufacturers of insulin glargine to help the sustainability of the 
healthcare system in the State of Minas Gerais. This can be through discounts, rebates or 
price: volume agreements, which is similar to activities in other countries [2, 6, 26, 55-58].  
We believe the findings of our systematic review, and its subsequent publication and ensuing 
debate, will help the authorities in the State of Minas Gerais achieve its aims. If there is 
delisting due to the reluctance by the manufacturers to appreciably lower the price of insulin 
glargine, we believe this review will provide the Judiciary with robust arguments and reasons 
to reduce the number of successful litigation cases brought by patients, which have been 
facilitated by pharmaceutical companies. 
We acknowledge that our systematic review only went up to July 2009. However, we do not 
believe any more recent randomised controlled trials, if they have been performed and 
published, will have altered our conclusions given the number of existing papers 
demonstrating no statistically significant advantage for insulin glargine for reducing both 
hypoglycaemia episodes and HbA1c levels (Table 3).  
CONCLUSIONS 
The present systematic review could not find any overall clinical benefits with insulin 
glargine compared to other investigated insulin formulations when glycaemic control and the 
frequency and severity of episodes of hypoglycaemia were analysed together. For these 
reasons, the SUS State Managers are advised to delist insulin glargine; alternatively, to 
negotiate a price reduction with the manufacturer to enhance its value. Publication of this 
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systematic review provides support for this decision as well as support to combat potential 
law suits if there cannot be satisfactory discussions.  
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Appendix 1 - Search strategy ± Pub Med 
Connector Field Parameter 
 All fields {Diabetes Mellitus Type 1} OR {Diabetes Mellitus tipo 1} 
AND All fields {insulin glargine} OR {insulina glargina} OR {insulin NPH} OR 
{insulin NPH} {insulina regular} OR {insulin regular} OR 
{insulina NPH animal} OR{insulina regular recombinante} OR 
{insulin animal NPH} OR {insulin recombinant NPH} OR 
{insulina NPH recombinante} OR {insulina regular animal} OR 
{insulin animal regular} OR {insulin recombinant regular} 
AND All fields Humans 
AND Language {english} OR {spanish} OR {portuguese} 
AND All fields {efficacy} OR {eficacia} OR {efetividade} OR {effectiveness} 
OR {cost-effectiveness} 
 
